Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamics of ranolazine in patients with angina pectoris and myocardial ischaemia

Trial Profile

Pharmacodynamics of ranolazine in patients with angina pectoris and myocardial ischaemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Angina pectoris; Myocardial ischaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Sep 2012 New trial record
    • 29 Aug 2012 Primary endpoint 'Coronary-flow-reserve' has been met according to results presented at the ESC Congress 2012.
    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top